GlassScriptPhysician profile
Carl Colton
NPI 1699856757
$2,744.24
in general payments reported to CMS, 2019-2025
25 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $343 · 2021: $363 · 2022: $603 · 2023: $153 · 2024: $24.89 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,014.08 | 2019-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.97 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $296.46 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $208.03 | 2019-2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $84.73 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $84.15 | 2020-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $77.70 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $74.78 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $73.70 | 2019-2020 | |
| Fujifilm Healthcare Americas Corporation | $72.28 | 2023 | Fujifilm |
| Pfizer INC. | $40.73 | 2019-2020 | |
| Qol Medical, LLC | $39.33 | 2019-2025 | Sucraid |
| Shionogi INC | $39.26 | 2019 | |
| Redhill Biopharma INC. | $34.09 | 2021 | |
| Daiichi Sankyo INC. | $33.27 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $25.00 | 2025 | Rezdiffra |
| Olympus America INC. | $22.19 | 2025 | Single Use Aspiration Needle Na-U200h |
| Palette Life Sciences, INC. | $22.00 | 2021 | |
| Novo Nordisk INC | $20.69 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $20.41 | 2025 | Voquezna |
| Amgen INC. | $18.64 | 2025 | Uplizna |
| Horizon Therapeutics Plc | $16.74 | 2022 | |
| Ucb, INC. | $16.34 | 2019 | |
| Braintree Laboratories, INC. | $16.15 | 2023 | Sutab |
| Gilead Sciences, INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Colton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.